NCT04524390Phase 2Completed
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2023-11-07Actual
Enrollment · participants75Actual
Source updated2025-03-19Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.